357P Bridging the gap between real-world studies (RWSs) and randomized controlled trials (RCTs) of 1st-line palbociclib+aromatase inhibitors (P+AI) in hormone receptor-positive (HR+)/HER2-negative(-) metastatic breast cancer (mBC)

S. Nucera(Breast Cancer Research Foundation), Daniele Generali(University of Trieste), Fabiola Giudici(University of Padua), M. Cristofanilli(Cornell University), Grazia Arpino(University of Naples Federico II), M. Lambertini(University of Genoa), Paolo Vigneri(Humanitas University), Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), Massimo Milani(University of Padua), H.S. Rugo(UCSF Helen Diller Family Comprehensive Cancer Center), Richard Tancredi(Istituti Ospitalieri di Cremona), Carla Strina(Istituti Ospitalieri di Cremona), B. Conte(Breast Cancer Research Foundation), G. Curigliano(European Institute of Oncology), T. Pascual(Hospital Clínic de Barcelona), Mariateresa Giuliano(University of Naples Federico II), L. Del Mastro(Ospedale Policlinico San Martino), A. Gennari(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), C. Criscitiello(European Institute of Oncology), F. Schettini(Breast Cancer Research Foundation)
Annals of Oncology
September 1, 2024
Cited by 0


Related Papers